The headline-grabbing field of immuno-oncology holds promises and challenges. Informative yet general articles (like this) reinforce what those who have spent decades in and around the industry have come to expect:

  • Significant capital
  • Intense competition
  • Lengthy approval timelines
  • High sales expectation
  • Higher company valuations
  • Need for patient stratification
  • And, most importantly, the possibility for profound impact on human health